Intellia Therapeutics (NTLA) Receivables (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Receivables data on file, last reported at $9.1 million in Q1 2026.

• Receivables for Q1 2026 came in at $9.1 million, down 1.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.1 million (down 1.09% YoY), and the FY2025 annual result was $9.5 million, up 31.94% from the prior year.
• Receivables eased to $9.1 million in Q1 2026 per NTLA's latest filing, from $9.5 million in the prior quarter.
• Over five years, Receivables peaked at $37.5 million in Q4 2023 and troughed at $1.8 million in Q1 2022.
• A 5-year average of $11.1 million and a median of $8.9 million in 2024 frame the typical range for Receivables.
• On a YoY basis, Receivables climbed as much as 599.71% in 2024 and fell as far as 77.26% in 2024.
• A 5-year view of Receivables shows it stood at $5.4 million in 2022, then jumped by 597.76% to $37.5 million in 2023, then plunged by 77.26% to $8.5 million in 2024, then rose by 11.54% to $9.5 million in 2025, then dropped by 4.21% to $9.1 million in 2026.
• Business Quant data shows NTLA's Receivables at $9.1 million in Q1 2026, $9.5 million in Q4 2025, and $11.0 million in Q3 2025.